同: APC

WordNet

a drug combination found in some over-the-counter headache remedies (aspirin and phenacetin and caffeine)
any mechanical force that tends to retard or oppose motion
the capacity of an organism to defend itself against harmful environmental agents; "these trees are widely planted because of their resistance to salt and smog"
the action of opposing something that you disapprove or disagree with; "he encountered a general feeling of resistance from many citizens"; "despite opposition from the newspapers he went ahead" (同)opposition
(psychiatry) an unwillingness to bring repressed feelings into conscious awareness
group action in opposition to those in power
the military action of resisting the enemys advance; "the enemy offered little resistance"
the degree of unresponsiveness of a disease-causing microorganism to antibiotics or other drugs (as in penicillin-resistant bacteria)
aerate (sewage) so as to favor the growth of organisms that decompose organic matter (同)aerate
make (substances) radioactive
make active or more active; "activate an old file"
make more adsorptive; "activate a metal"
the 3rd letter of the Roman alphabet (同)c
(music) the keynote of the scale of C major
a general-purpose programing language closely associated with the UNIX operating system
rendered active; e.g. rendered radioactive or luminescent or photosensitive or conductive
(of e.g. a molecule) made reactive or more reactive (同)excited
(military) set up and placed on active assignment; "a newly activated unit"
(of sewage) treated with aeration and bacteria to aid decomposition
any of a large group of nitrogenous organic compounds that are essential constituents of living cells; consist of polymers of amino acids; essential in the diet of animals for growth and for repair of tissues; can be obtained from meat and eggs and milk and legumes; "a diet high in protein"

PrepTutorEJDIC

アスピリン(Aspirin)・フェナセチン(Phenacetin)・カフェイン(Caffeine)混合の鎮痛解熱剤
〈U〉〈C〉(…に)『抵抗』(『反抗』)『すること』;(…を)『こらえること』《+『to』(『against』)+『名』(do『ing』)》 / 〈U〉(病気などに対する)『抵抗力』《+『against』(『to』)+『名』》 / 〈U〉〈C〉(またresistance movement)(権力・圧制に対する)抵抗運動,レジスタンス / 〈U〉(空気の)抵抗;(電気の)抵抗
…'を'活動的にする / …‘に'放射能を与える / 〈物質〉'を'活性化する
carbonの化学記号
蛋白(たんばく)質

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2018/09/24 17:45:22」(JST)

wiki en

Activated protein C resistance (APCR) is a hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). This results in an increased risk of venous thrombosis, which can cause problems with circulation, such as pulmonary embolism.^[1]

The disorder can be acquired or inherited, the hereditary form having an autosomal dominant inheritance pattern.^[2]

Presentation

Associated conditions

An estimated 64 percent of patients with venous thromboembolism may have activated protein C resistance.^[3]

Pathophysiology

Activated protein C (with protein S as a cofactor) degrades Factor Va and Factor VIIIa. Activated protein C resistance is the inability of protein C to cleave Factor Va and/or Factor VIIIa, which allows for longer duration of thrombin generation and may lead to a hypercoagulable state. This may be hereditary or acquired.^[4] The best known and most common hereditary form is Factor V Leiden. Acquired forms occur in the presence of elevated Factor VIII concentrations.

Diagnosis

"APC(Activated protein C) ratio: To diagnose functional assays | PCR(Polymerase chain reaction)/ Restriction enzyme analysis: To detect the specific genetic anomaly responsible for FVL(factor V Leiden) "

Treatment

References

^ Dahlbäck B (2003). "The discovery of activated protein C resistance". J. Thromb. Haemost. 1 (1): 3–9. doi:10.1046/j.1538-7836.2003.00016.x. PMID 12871530.
^ Koster T, Rosendaal FR, De Ronde H, Briët E, Vandenbroucke JP, Bertina RM (December 1993). "Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study". Lancet. 342 (8886–8887): 1503–6. doi:10.1016/S0140-6736(05)80081-9. ISSN 0140-6736. PMID 7902898.
^ Sheppard DR (2000). "Activated protein C resistance: the most common risk factor for venous thromboembolism". J Am Board Fam Pract. 13 (2): 111–5. doi:10.3122/15572625-13-2-111. PMID 10764192.
^ Nicolaes GA, Dahlbäck B (2003). "Congenital and acquired activated protein C resistance". Semin Vasc Med. 3 (1): 33–46. doi:10.1055/s-2003-38331. PMID 15199491.

External links

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 第V因子ライデンと活性化プロテインC抵抗性 factor v leiden and activated protein c resistance
2. 静脈血栓症が確認された患者の後天的危険因子および遺伝的危険因子の評価 evaluating patients with established venous thromboembolism for acquired and inherited risk factors
3. 妊娠中の先天性血栓性素因 inherited thrombophilias in pregnancy
4. 妊娠における深部静脈血栓症：疫学、病因、および診断 deep vein thrombosis in pregnancy epidemiology pathogenesis and diagnosis
5. 静脈血栓塞栓症の患者における理論的根拠と無期限の抗凝固の適応 rationale and indications for indefinite anticoagulation in patients with venous thromboembolism

English Journal

Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).

Maryamchik E, Rosenbaum MW, Van Cott EM.
Archives of pathology & laboratory medicine.Arch Pathol Lab Med.2017 Sep 18. doi: 10.5858/arpa.2016-0616-OA. [Epub ahead of print]
CONTEXT: - Rivaroxaban causes a false increase in activated protein C resistance (APCR) ratios and protein S activity.OBJECTIVE: - To investigate whether this increase masks a diagnosis of factor V Leiden (FVL) or protein S deficiency in a "real-world" population of patients undergoing rivaroxaban t
PMID 28920711

Prevalence of Factor V Genetic Variants Associated With Indian APCR Contributing to Thrombotic Risk.

Sharma A1, Bhakuni T2, Biswas A3, Ranjan R1, Kumar R1, Kishore K1, Mahapatra M1, Jairajpuri MA2, Saxena R1.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.Clin Appl Thromb Hemost.2017 Sep;23(6):596-600. doi: 10.1177/1076029615623376. Epub 2015 Dec 23.
PMID 26699866

Primary Thrombophilia in México XI: Activated Protein C Resistance Phenotypes are Multifactorial.

Vallejo-Villalobos MF1,2, León-Peña A1,3,4, León-González M1,2,4, Núñez-Cortés AK1,3,4, Olivares-Gazca JC1,2,4, Valdés-Tapia P1, Garcés-Eisele J1,2, Ruiz-Argüelles A1,2,4, Ruiz-Argüelles GJ1,2,4,5.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion.Indian J Hematol Blood Transfus.2017 Sep;33(3):375-379. doi: 10.1007/s12288-016-0767-7. Epub 2016 Dec 19.
PMID 28824240

Japanese Journal

Transcriptome Analysis of WIPK/SIPK-Suppressed Plants Reveals Induction by Wounding of Disease Resistance-Related Genes Prior to the Accumulation of Salicylic Acid

Katou Shinpei,Asakura Nobuhide,Kojima Tomoya,Mitsuhara Ichiro,Seo Shigemi
PLANT AND CELL PHYSIOLOGY 54(6), 1005-1015, 2013-06-00
… Salicylic acid (SA) plays a key role in plant resistance to pathogens. … Accumulation of SA is induced by wounding in tobacco plants in which the expression of WIPK and SIPK, two mitogen-activated protein kinases, is suppressed. … SA accumulation started around 12 h after wounding and was inhibited by cycloheximide (CHX), a protein synthesis inhibitor. …
NAID 120005312278

Isolation, identification, and biological evaluation of Nrf2-ARE activator from the leaves of green perilla (Perilla frutescens var. crispa f. viridis)

Izumi Yasuhiko,Matsumura Atsuko,Wakita Seiko,Akagi Ken-Ichi,Fukuda Hiroyuki,Kume Toshiaki,Irie Kazuhiro,Takada-Takatori Yuki,Sugimoto Hachiro,Hashimoto Tadashi,Akaike Akinori
Free radical biology & medicine 53(4), 669-679, 2012-06-27
… Inhibition of the p38 mitogen-activated protein kinase pathway abolished ARE activation, the induction of γ-GCS and NQO1, and the cytoprotective effect brought about by DDC. … Thus, this study demonstrated that DDC contained in green perilla enhanced cellular resistance to oxidative damage through activation of the Nrf2-ARE pathway. …
NAID 120004462161

Isolation and characterization of an asparagine-rich protein that regulates hypersensitive cell death-mediated resistance in Nicotiana plants

Komori Daisuke,Nishihara Masahiro,Takahashi Akiko [他],GUPTA Meenu,YOSHIOKA Hirofumi,MIZUMOTO Hiroyuki,OHNISHI Kouhei,HIKICHI Yasufumi,KIBA Akinori
Plant biotechnology 29(3), 293-300, 2012-06-25
… We designated this protein NbARP (N. … benthamiana asparagine-rich protein). … Silencing of NbARP reduced induction of HR-cell death by Agrobacterium tumefaciens-mediated transient expression of HR elicitors and a constitutively active form of mitogen activated protein kinase kinase. …
NAID 10030804810

Related Pictures

★リンクテーブル★

リンク元	「活性型プロテインC抵抗性」
関連記事	「C」「activated」「activate」「Cs」「Cd」

「活性型プロテインC抵抗性」

Activated protein C resistance (APCR)
Synonyms	ICD9= 289.81
	Protein C Anticoagulant Pathway: Thrombin escaping from a site of vascular injury binds to its receptor thrombomodulin (TM) on the intact cell surface. As a result, thrombin loses its procoagulant properties and instead becomes a potent activator of protein C. Activated protein C (APC) functions as a circulating anticoagulant, which specifically degrades and inactivates the phospholipid-bound factors Va and VIIIa. This effectively down-regulates the coagulation cascade and limits clot formation to sites of vascular injury. T = Thrombin, PC= Protein C, Activated Protein C= APC, PS= Protein S

　　[★]

英: activated protein C resistance
関: 活性化プロテインC不応症

「C」

　　[★]

炭素 carbon
シトシン cytosine
システイン cysteine
シチジン
セルシウス度摂氏 degrees Celsius degree C
産婦人科領域で「子宮外頚子宮外頚部 exocervix」を表現するための略語

「activated」

　　[★]

adj.

活性化の、活性化型の、賦活化の

関: activate、activated form、activation、turn on

「activate」

　　[★]

v.

活性化する、賦活化する、賦活する

関: activated、activation、turn on

「Cs」

　　[★] セシウム, caesium, cesium 　

「Cd」

　　[★] カドミウム

関: cadmium

[1] Dahlbäck B (2003). "The discovery of activated protein C resistance". J. Thromb. Haemost. 1 (1): 3–9. doi:10.1046/j.1538-7836.2003.00016.x. PMID 12871530.

[2] Koster T, Rosendaal FR, De Ronde H, Briët E, Vandenbroucke JP, Bertina RM (December 1993). "Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study". Lancet. 342 (8886–8887): 1503–6. doi:10.1016/S0140-6736(05)80081-9. ISSN 0140-6736. PMID 7902898.

[3] Sheppard DR (2000). "Activated protein C resistance: the most common risk factor for venous thromboembolism". J Am Board Fam Pract. 13 (2): 111–5. doi:10.3122/15572625-13-2-111. PMID 10764192.

[4] Nicolaes GA, Dahlbäck B (2003). "Congenital and acquired activated protein C resistance". Semin Vasc Med. 3 (1): 33–46. doi:10.1055/s-2003-38331. PMID 15199491.

匿名

検索

案内

案内

activated protein C resistance